Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554421 | 0.83 | SHBG (0.50) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL6706329 | 0.79 | SHBG (0.44) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL11506104 | 0.75 | LMNA (0.55) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL11507827 | 0.73 | AR (0.52) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL11506637 | 0.71 | AR (0.50) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL7793500 | 0.71 | SHBG (0.42) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL11506894 | 0.71 | AR (0.49) | SHBGCYP19A1LMNAMAPTHIF1A | |
| SCHEMBL11743506 | 0.70 | SHBG (0.53) | SHBGCYP19A1LMNAMAPTNR3C1 | |
| SCHEMBL11743496 | 0.70 | SHBG (0.53) | SHBGCYP19A1LMNAMAPTNR3C1 | |
| SCHEMBL11013929 | 0.70 | SHBG (0.53) | SHBGCYP19A1LMNAMAPTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | AVENTIS PHARMA S.A. | 2004-12-02 | — | — | US | claimed |
| EP-0863760-B1 | USE OF ANTIMINERALOCORTICOID COMPOUNDS AGAINST DRUG WITHDRAWAL SYNDROME | AVENTIS PHARMA SA (FR) | 2001-12-05 | — | — | EP | claimed |
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | AVENTIS PHARMA S.A. | 2004-12-02 | — | — | US | disclosed |
| US-6759399-B1 | USING SUCH AS GAMMA-LACTONE OF 10-ETHYNYL-17-HYDROXY-3-OXO-19-NOR-17-PREGNA-4,9(11)-DIENE-21-CARBOXYLIC ACID | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | disclosed |
| US-6147066-A | Use of antimineralocorticoid compounds against drug withdrawal syndrome | Roussel, Hoechst Marion (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242552-A1 | New use of antimineralocorticoid compounds against narcotic withdrawal syndrome | OPRM1, PNMT, SLC6A11 | SHBG 13/4885CYP19A1 2666/4885LMNA 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.